Abstract
In recent years, the development of more effective drugs has provided a better prognosis and an increase in life expectancy for patients at all-stages of cancer. On the other hand, the price for the improving effectiveness of therapies against malignant tumors is the development of severe and potentially life-threatening drug reactions. Among these, cardiac toxic effects have recently gained particular attention. The term cardiotoxicity includes many possible pathological manifestations, but the most frequent is the reduction in cardiac function, potentially leading to heart failure and death. Importantly, the development of cardiac dysfunction may occur immediately after drug administration, or after years. The purpose of this review is to discuss the clinical features of cardiotoxicity, its molecular basis and novel possible strategies to reduce the likelihood of serious cardiac complications.
Keywords: Anthracyclines, anti-neoplastic drugs, cancer, cardiotoxicity, chemotherapy, cyclophosphamide, heart failure, fluoropirimidines, oxidative stress, Trastuzumab, taxanes.
Current Vascular Pharmacology
Title:Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management
Volume: 12 Issue: 1
Author(s): Cinzia Perrino, Gabriele G. Schiattarella, Fabio Magliulo, Federica Ilardi, Giuseppe Carotenuto, Giuseppe Gargiulo, Federica Serino, Marco Ferrone, Fernando Scudiero, Andreina Carbone, Bruno Trimarco and Giovanni Esposito
Affiliation:
Keywords: Anthracyclines, anti-neoplastic drugs, cancer, cardiotoxicity, chemotherapy, cyclophosphamide, heart failure, fluoropirimidines, oxidative stress, Trastuzumab, taxanes.
Abstract: In recent years, the development of more effective drugs has provided a better prognosis and an increase in life expectancy for patients at all-stages of cancer. On the other hand, the price for the improving effectiveness of therapies against malignant tumors is the development of severe and potentially life-threatening drug reactions. Among these, cardiac toxic effects have recently gained particular attention. The term cardiotoxicity includes many possible pathological manifestations, but the most frequent is the reduction in cardiac function, potentially leading to heart failure and death. Importantly, the development of cardiac dysfunction may occur immediately after drug administration, or after years. The purpose of this review is to discuss the clinical features of cardiotoxicity, its molecular basis and novel possible strategies to reduce the likelihood of serious cardiac complications.
Export Options
About this article
Cite this article as:
Perrino Cinzia, Schiattarella G. Gabriele, Magliulo Fabio, Ilardi Federica, Carotenuto Giuseppe, Gargiulo Giuseppe, Serino Federica, Ferrone Marco, Scudiero Fernando, Carbone Andreina, Trimarco Bruno and Esposito Giovanni, Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management, Current Vascular Pharmacology 2014; 12 (1) . https://dx.doi.org/10.2174/157016111201140327163302
DOI https://dx.doi.org/10.2174/157016111201140327163302 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of Steroidal Cytochrome P450 Enzymes as Targets for Drug Development
Recent Patents on Anti-Cancer Drug Discovery Effects of Mesenchymal Stromal Cells on Diabetic Cardiomyopathy
Current Pharmaceutical Design Stimulated CB1 Cannabinoid Receptor Inducing Ischemic Tolerance and Protecting Neuron from Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Editorial [Carotid Intima-Media Thickness and Ezetimibe: The End of a Misunderstanding?]
Current Vascular Pharmacology Amniotic Fluid Stem Cells: a Promising Therapeutic Resource for Cell-Based Regenerative Therapy
Current Pharmaceutical Design Long-Acting Beta-Agonists and their Association with Inhaled Corticosteroids in COPD
Current Medicinal Chemistry Lone Atrial Fibrillation- A Diagnosis of Exclusion
Current Pharmaceutical Design Cardiac MRI in Autoimmune Diseases: Where Are We Now?
Current Cardiology Reviews Use of Deoxyribozymes for Gene Knockdown
Medicinal Chemistry Reviews - Online (Discontinued) Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Nitric Oxide, Malnutrition and Chronic Renal Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design Mechanisms of Neurodegeration in Type 2 Diabetes and the Neuroprotective Potential of Dipeptidyl Peptidase 4 Inhibitors
Current Medicinal Chemistry Climate Changes and Human Health: A Review of the Effect of Environmental Stressors on Cardiovascular Diseases Across Epidemiology and Biological Mechanisms
Current Pharmaceutical Design Perspectives on Emerging Biomarkers for Non-Invasive Assessment of Embryo Viability in Assisted Reproduction
Current Molecular Medicine Effects of Thiazolidinediones Beyond Glycaemic Control
Current Pharmaceutical Design Oral IIa and Xa Inhibitors for Prevention of Stroke in Atrial Fibrillation: Clinical Studies and Regulatory Considerations
Current Clinical Pharmacology Current Concepts in SLE Thrombocytopenia: From Pathophysiology to Therapeutic Interventions
Current Rheumatology Reviews The Role of Klotho Protein in Chronic Kidney Disease: Studies in Animals and Humans
Current Protein & Peptide Science